Market Research Logo

LG Life Sciences, Ltd. - Product Pipeline Review - 2015

LG Life Sciences, Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘LG Life Sciences, Ltd. - Product Pipeline Review - 2015’, provides an overview of the LG Life Sciences, Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of LG Life Sciences, Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of LG Life Sciences, Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of LG Life Sciences, Ltd.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the LG Life Sciences, Ltd.’s pipeline products
Reasons to buy
  • Evaluate LG Life Sciences, Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of LG Life Sciences, Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the LG Life Sciences, Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of LG Life Sciences, Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of LG Life Sciences, Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of LG Life Sciences, Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


LG Life Sciences, Ltd. Snapshot
LG Life Sciences, Ltd. Overview
Key Information
Key Facts
LG Life Sciences, Ltd. - Research and Development Overview
Key Therapeutic Areas
LG Life Sciences, Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
LG Life Sciences, Ltd. - Pipeline Products Glance
LG Life Sciences, Ltd. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
LG Life Sciences, Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
LG Life Sciences, Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
LG Life Sciences, Ltd. - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
LG Life Sciences, Ltd. - Drug Profiles
somatropin SR
Product Description
Mechanism of Action
R&D Progress
(gemigliptin + metformin hydrochloride)
Product Description
Mechanism of Action
R&D Progress
(gemigliptin + rosuvastatin calcium)
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar
Product Description
Mechanism of Action
R&D Progress
somatropin (recombinant)
Product Description
Mechanism of Action
R&D Progress
(lercanidipine hydrochloride + valsartan)
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2a SR
Product Description
Mechanism of Action
R&D Progress
LC-280126
Product Description
Mechanism of Action
R&D Progress
LD-02GIFRO
Product Description
Mechanism of Action
R&D Progress
nivocasan
Product Description
Mechanism of Action
R&D Progress
(gemigliptin + sulfonylureas)
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar
Product Description
Mechanism of Action
R&D Progress
LC-231306
Product Description
Mechanism of Action
R&D Progress
LC-350189
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar
Product Description
Mechanism of Action
R&D Progress
LC-280391
Product Description
Mechanism of Action
R&D Progress
NecX
Product Description
Mechanism of Action
R&D Progress
Small Molecules For Obesity
Product Description
Mechanism of Action
R&D Progress
exenatide SR
Product Description
Mechanism of Action
R&D Progress
LC-34AD3
Product Description
Mechanism of Action
R&D Progress
LC-54AID3
Product Description
Mechanism of Action
R&D Progress
rituximab biosimilar
Product Description
Mechanism of Action
R&D Progress
Small Molecule To inhibit PAR-1 for Atherothrombosis
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit VEGF for Cancer
Product Description
Mechanism of Action
R&D Progress
LG Life Sciences, Ltd. - Pipeline Analysis
LG Life Sciences, Ltd. - Pipeline Products by Target
LG Life Sciences, Ltd. - Pipeline Products by Route of Administration
LG Life Sciences, Ltd. - Pipeline Products by Molecule Type
LG Life Sciences, Ltd. - Pipeline Products by Mechanism of Action
LG Life Sciences, Ltd. - Recent Pipeline Updates
LG Life Sciences, Ltd. - Dormant Projects
LG Life Sciences, Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
LG Life Sciences, Ltd., Key Information
LG Life Sciences, Ltd., Key Facts
LG Life Sciences, Ltd. - Pipeline by Indication, 2015
LG Life Sciences, Ltd. - Pipeline by Stage of Development, 2015
LG Life Sciences, Ltd. - Monotherapy Products in Pipeline, 2015
LG Life Sciences, Ltd. - Combination Treatment Modalities in Pipeline, 2015
LG Life Sciences, Ltd. - Partnered Products in Pipeline, 2015
LG Life Sciences, Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
LG Life Sciences, Ltd. - Out-Licensed Products in Pipeline, 2015
LG Life Sciences, Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
LG Life Sciences, Ltd. - Pre-Registration, 2015
LG Life Sciences, Ltd. - Phase III, 2015
LG Life Sciences, Ltd. - Phase II, 2015
LG Life Sciences, Ltd. - Phase I, 2015
LG Life Sciences, Ltd. - Preclinical, 2015
LG Life Sciences, Ltd. - Discovery, 2015
LG Life Sciences, Ltd. - Unknown, 2015
LG Life Sciences, Ltd. - Pipeline by Target, 2015
LG Life Sciences, Ltd. - Pipeline by Route of Administration, 2015
LG Life Sciences, Ltd. - Pipeline by Molecule Type, 2015
LG Life Sciences, Ltd. - Pipeline Products by Mechanism of Action, 2015
LG Life Sciences, Ltd. - Recent Pipeline Updates, 2015
LG Life Sciences, Ltd. - Dormant Developmental Projects,2015
LG Life Sciences, Ltd., Other Locations
LG Life Sciences, Ltd., Subsidiaries
List of Figures
LG Life Sciences, Ltd. - Pipeline by Top 10 Indication, 2015
LG Life Sciences, Ltd. - Pipeline by Stage of Development, 2015
LG Life Sciences, Ltd. - Monotherapy Products in Pipeline, 2015
LG Life Sciences, Ltd. - Combination Treatment Modalities in Pipeline, 2015
LG Life Sciences, Ltd. - Pipeline by Top 10 Target, 2015
LG Life Sciences, Ltd. - Pipeline by Top 10 Route of Administration, 2015
LG Life Sciences, Ltd. - Pipeline by Top 10 Molecule Type, 2015
LG Life Sciences, Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report